Drugs / Fluarix Quadrivalent Influenza vaccine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT03698279 Comparator | Oct 2018 → Oct 2019 | influenza | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fluarix Quadrivalent Influenza vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03698279 ↗ |
| Known as | QIV-SD | “Fluarix Quadrivalent Influenza vaccine (Unadjuvanted QIV-SD) (Inactivated)” NCT03698279 ↗ |
| Modality | Vaccine | “standard-dose quadrivalent influenza vaccine” NCT03698279 ↗ |
| Route | Intramuscular | “Route of administration: IM” NCT03698279 ↗ |